Juno and Kite have near-term technologies only connected to 10% of the cancer market. They also dilute each other. Make that 5%. They work on leukemia and lymphoma. They do this by going after antigen(s) that make up both healthy and cancerous cells. They kill all healthy B-cells in the body. I can’t impress on people enough how this is not the way it works with solid cancer. One poster here thinks Car-Ts can work on solid tumors, but they have not come close to approval. They can’t attack solid tumors the same way they attack lymphoma and leukemia or they would always kill the patient. Instead, just like peptide vaccines or restricted DCVaccines, they are trying to find the right antigens and neoantigens to attack and only kill cancer cells. Just like Celldex and Immunocellular, they have not found the right cocktail of antigen(s) and neoantigen(s).
DCVax, on the other hand, has a product that can target 90% to 100% of the cancer market without artificially selecting things like killing all healthy B-cells in the body to win. Essentially, 1st and second generation Car-T’s are being asked to do things the body would never do because of nature’s evolutionary safety defaults. DCVax instead works within the evolutionary safety defaults.